Related Experiment Video
Updated: May 28, 2026
02:44
Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
Published on: July 26, 2024
Model-Integrated Bioequivalence (MIBE) in Generic Drug Research: Can We Ease the Bioequivalence Burden?
Sivacharan Kollipara1, Rajkumar Boddu1, Chandra Teja Uppuluri1
1Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad 500090, Telangana, India.
Pharmaceutics
|May 27, 2026
Summary
Model-Integrated Bioequivalence (MIBE) uses quantitative modeling to support generic drug approval. Population pharmacokinetic (POP-PK) modeling offers a practical approach for bioequivalence determination, especially for complex formulations, enabling faster market entry.
Area of Science:
- Pharmacokinetics and Drug Development
- Regulatory Science
- Quantitative Modeling
Background:
- Bioequivalence (BE) studies are crucial for Abbreviated New Drug Application (ANDA) submissions but can be complex and time-consuming.
- Quantitative modeling and simulation are increasingly used to provide regulatory evidence in generic drug development.
- Model-Integrated Bioequivalence (MIBE) leverages modeling to directly support BE determination.
Purpose of the Study:
- To provide a contemporary overview of MIBE in generic drug development.
- To emphasize the role of population pharmacokinetic (POP-PK) modeling in MIBE.
- To discuss evolving regulatory perspectives on model-based evidence for BE assessment.
Main Methods:
- Review of MIBE frameworks, with a focus on POP-PK-based approaches.
- Discussion of quantitative modeling techniques applicable to MIBE.
- Illustration of MIBE through six hypothetical case examples for diverse formulations and BE scenarios.
Main Results:
- POP-PK modeling is gaining traction for MIBE implementation, particularly when mechanistic models are challenging.
- MIBE, especially using POP-PK, can address specific regulatory questions for both complex and non-complex generic formulations.
- The review highlights the integration of model-based evidence for BE assessment.
Conclusions:
- MIBE, particularly with POP-PK, offers a viable strategy for bioequivalence determination in generic drug development.
- This approach can streamline the regulatory process, facilitating faster approval of generic medicines.
- The manuscript encourages the adoption of MIBE by generic companies for timely market access.
Related Concept Videos
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:20Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
01:17Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...